Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow

Stem Cells

Volumn 27, Issue 9, 2009, Pages 2331-2341

  Bieback, Karen ^a   Hecker, Andrea ^a   Kocaömer, Asli ^a   Lannert, Heinrich ^a   Schallmoser, Katharina ^b   Strunk, Dirk ^b   Klüter, Harald ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Bone marrow; Fetal bovine serum; Human serum; Mesenchymal stromal cells; Platelet derived factors; Pooled platelet lysate

Indexed keywords

ADAPALENE; CYTOKINE; TELOMERASE;

ARTICLE; BONE MARROW; CELL CULTURE; CELL DIFFERENTIATION; CELL EXPANSION; CELL ISOLATION; CELL MATURATION; CELL PROLIFERATION; CELL SELECTION; CELL STRUCTURE; CELL TRANSFORMATION; COLONY FORMING UNIT; CONTROLLED STUDY; ENZYME ACTIVITY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOMODULATION; MESENCHYME CELL; MONONUCLEAR CELL; OSTEOBLAST; PHENOTYPE; SERUM; STROMA CELL; T LYMPHOCYTE; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; BONE MARROW; CATTLE; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; HUMANS; MESENCHYMAL STEM CELLS; PLATELET-DERIVED GROWTH FACTOR; SERUM; STROMAL CELLS;

BOVINAE;

EID: 70349850496     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.139     Document Type: Article

References (54)

1. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: The state of transdifferentiation and modes of tissue repair - current views. Stem Cells 2007;25:2896-2902.
2. Reinisch A, Bartmann C, Rohde E et al. Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application. Regen Med 2007;2:371-382. (Pubitemid 47304957)
3. Schallmoser K, Bartmann C, Rohde E et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007;47:1436-1446. (Pubitemid 47101060)
4. Schallmoser K, Rohde E, Reinisch A et al. Rapid large-scale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng Part C Methods 2008;14:185-196.
5. Honn KV, Singley JA, Chavin W. Fetal bovine serum: A multivariate standard. Proc Soc Exp Biol Med 1975;149:344-347.
6. Heiskanen A, Satomaa T, Tiitinen S et al. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 2007;25:197-202. (Pubitemid 46052991)
7. Sundin M, Ringden O, Sundberg B et al. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 2007;92:1208-1215. (Pubitemid 350144179)
8. Note for guidance on the use of bovine serum in the manufacture of human medicinal products. EMEA CPMP/BWP/1793/02; 2003.
9. Note for the guidance on minimising risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products EMEA/410/01 rev. 2; 2004.
10. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006;355:1730-1735.
11. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002;99:8932-8937.
12. Mannello F, Tonti GA. Concise review: No breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold!Stem Cells 2007;25:1603-1609.
13. Guideline on human cell-based medicinal products. EMEA/CHMP/410869/2006; 2008.
14. Stute N, Holtz K, Bubenheim M et al. Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use. Exp Hematol 2004;32:1212-1225. (Pubitemid 39601127)
15. Lin HT, Tarng YW, Chen YC et al. Using human plasma supplemented medium to cultivate human bone marrow-derived mesenchymal stem cell and evaluation of its multiple-lineage potential. Transplant Proc 2005;37:4504-4505.
16. Phadnis SM, Joglekar MV, Venkateshan V et al. Human umbilical cord blood serum promotes growth, proliferation, as well as differentiation of human bone marrow-derived progenitor cells. In Vitro Cell Dev Biol Anim 2006;42:283-286. (Pubitemid 46224680)
17. Doucet C, Ernou I, Zhang Y et al. Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005;205:228-236. (Pubitemid 41428905)
18. Bernardo ME, Avanzini MA, Perotti C et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: Further insights in the search for a fetal calf serum substitute. J Cell Physiol 2007;211:121-130. (Pubitemid 46363901)
19. Capelli C, Domenghini M, Borleri G et al. Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. Bone Marrow Transplant 2007;40:785-791. (Pubitemid 47521539)
20. Gregory CA, Reyes E, Whitney MJ et al. Enhanced engraftment of mesenchymal stem cells in a cutaneous wound model by culture in allogenic species-specific serum and administration in fibrin constructs. Stem Cells 2006;24:2232-2243. (Pubitemid 44527476)
21. Lange C, Cakiroglu F, Spiess AN et al. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerativemedicine. J Cell Physiol 2007;213:18-26. (Pubitemid 47378788)
22. Davenport M, Verrier S, Droeser R et al. Platelet lysate as a serum substitute for 2D static and 3D perfusion culture of stromal vascular fraction cells from human adipose tissue. Tissue Eng Part A 2009;15:869-875.
23. Müller I, Kordowich S, Holzwarth C et al. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 2006;8:437-444. (Pubitemid 44596996)
24. Oreffo ROC, Virdi AS, Triffitt JT. Modulation of osteogenesis and adipogenesis by human serum in human bone marrow cultures. Eur J Cell Biol 1997;74:251-261. (Pubitemid 27490216)
25. Harrison P, Cramer EM. Platelet alpha-granules. Blood Rev 1993;7:52-62.
26. Janetzko K, Kluter H, van Waeg G et al. Fully automated processing of buffy-coat-derived pooled platelet concentrates. Transfusion 2004;44:1052-1058. (Pubitemid 38823813)
27. Kocaoemer A, Kern S, Kluter H et al. Human AB serum and thrombin- activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007;25:1270-1278. (Pubitemid 46684887)
28. Shahdadfar A, Fronsdal K, Haug T et al. In vitro expansion of human mesenchymal stem cells: Choice of serum is a determinant of cell proliferation, differentiation, gene expression, and transcriptome stability. Stem Cells 2005;23:1357-1366.
29. Lannert H, Able T, Becker S et al. Optimizing BM harvesting from normal adult donors. Bone Marrow Transplant 2008;42:443-447.
30. Kern S, Eichler H, Stoeve J et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006;24:1294-1301. (Pubitemid 44464698)
31. Bieback K, Kern S, Kluter H et al. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004;22:625-634. (Pubitemid 39014578)
32. Nguyen XD, Eichler H, Dugrillon A et al. Flow cytometric analysis of T cell proliferation in a mixed lymphocyte reaction with dendritic cells. J Immunol Methods 2003;275:57-68. (Pubitemid 36351542)
33. Bartmann C, Rohde E, Schallmoser K et al. Two steps to functional mesenchymal stromal cells for clinical application. Transfusion 2007;47:1426-1435. (Pubitemid 47101059)
34. Bieback K, Schallmoser K, Klüter H, et al. Clinical protocols for the isolation and expansion of mesenchymal stromal cells. Transfusion Med Hemother. 2008;35:286-295.
35. Carrancio S, Lopez-Holgado N, Sanchez-Guijo FM et al. Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification. Exp Hematol 2008;36:1014-1021.
36. Yamaguchi M, Hirayama F, Wakamoto S et al. Bone marrow stromal cells prepared using AB serum and bFGF for hematopoietic stem cells expansion. Transfusion 2002;42:921-927.
37. Dahl JA, Duggal S, Coulston N et al. Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. Int J Dev Biol 2008;52:1033-1042.
38. Trombi L, Pacini S, Montali M et al. Selective culture of mesodermal progenitor cells (MPCs). Stem Cells Dev 2009 [Epub ahead of print].
39. Kobayashi T, Watanabe H, Yanagawa T et al. Motility and growth of human bone-marrow mesenchymal stem cells during ex vivo expansion in autologous serum. J Bone Joint Surg Br 2005;87:1426-1433. (Pubitemid 41511812)
40. Kuznetsov SA, Mankani MH, Robey PG. Effect of serum on human bone marrow stromal cells: Ex vivo expansion and in vivo bone formation. Transplantation 2000;70:1780-1787. (Pubitemid 32064834)
41. Coppinger JA, Cagney G, Toomey S et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004;103:2096-2104. (Pubitemid 38326225)
42. Italiano JE Jr, Richardson JL, Patel-Hett S et al. Angiogenesis is regulated by a novel mechanism: Pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008;111:1227-1233. (Pubitemid 351213404)
43. Levy O, Dvir T, Tsur-Gang O et al. Signal transducer and activator of transcription 3-A key molecular switch for human mesenchymal stem cell proliferation. Int J Biochem Cell Biol 2008;40:2606-2618.
44. Ng F, Boucher S, Koh S et al. PDGF, TGF-beta, and Fgf signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): Transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 2008;112:295-307.
45. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
46. Gronthos S, Simmons PJ, Graves SE et al. Integrin-mediated interactions between human bone marrow stromal precursor cells and the extracellular matrix. Bone 2001;28:174-181. (Pubitemid 32140973)
47. Thomas RJ, Hourd PC, Williams DJ. Application of process quality engineering techniques to improve the understanding of the in vitro processing of stem cells for therapeutic use. J Biotechnol 2008;136:148-155.
48. Rubio D, Garcia-Castro J, Martin MC et al. Spontaneous human adult stem cell transformation. Cancer Res 2005;65:3035-3039. (Pubitemid 40524580)
49. Zhang ZX, Guan LX, Zhang K et al. Cytogenetic analysis of human bone marrow-derived mesenchymal stem cells passaged in vitro. Cell Biol Int 2007;31:645-648. (Pubitemid 46660640)
50. Meza-Zepeda LA, Noer A, Dahl JA et al. High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. J Cell Mol Med 2008;12:553-563. (Pubitemid 351555134)
51. Poloni A, Maurizi G, Rosini V et al. Selection of CD271(+) cells and human AB serum allows a large expansion of mesenchymal stromal cells from human bone marrow. Cytotherapy 2009;11:153-162.
52. Quirici N, Soligo D, Bossolasco P et al. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 2002;30:783-791. (Pubitemid 34835685)
53. Janetzko K, Cazenave JP, Kluter H et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45:1443-1452. (Pubitemid 44194647)
54. von Bonin M, Stolzel F, Goedecke A et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009;43:245-251.